uniQure N.V. (QURE) · Nov 2, 2026 · Other events

uniQure FDA accepts Huntington’s BLA, but advisory panel looms

Priority review granted — PDUFA target date May 1, 2027

uniQure’s FDA acceptance and priority review move its Huntington’s gene therapy toward a May 2027 decision, while a confirmatory trial remains critical.

uniQure is a gene-therapy company whose business now hinges heavily on ifezuntirgene inilparvovec, its lead Huntington’s disease program. Before this filing, the FDA had already indicated that a BLA submission under accelerated approval was reasonable, and the company had targeted the third quarter of 2026 for submission.

The regulatory path has advanced from planned submission to an active, expedited review. The FDA accepted the BLA, granted Priority Review, and set a May 1, 2027 PDUFA action date. 〔0〕 That is a meaningful step beyond the previously expected filing, but it is not an approval or a conclusion that the clinical evidence is sufficient.

The confirmatory-trial requirement is now more concrete, not eliminated. uniQure and the FDA aligned on a randomized standard-of-care study of approximately 200 patients, with Total Functional Capacity measured at 36 months as the primary endpoint; screening is planned by the end of 2026. 〔1〕 This gives the accelerated-approval route a defined validation mechanism, while also making execution, enrollment, funding, and eventual trial success central to the story.

An advisory committee could add scrutiny before the decision. The FDA is tentatively planning to discuss the application at an Advisory Committee meeting. 〔2〕 That does not change the May 1, 2027 target, but it means the application will likely face a visible external review of the small Phase I/II evidence base and its external-control comparison rather than a quiet agency decision.

Key filing factCurrentComparison
PDUFA action date (PDUFA)May 1, 2027—
Confirmatory enrollment (TFC)~200 patients—
Treatment:standard-of-care ratio (TFC)2:1—
Phase I/II patients dosed (Clinical studies)51—

Bottom line: This is a real regulatory de-risking step and slightly strengthens uniQure’s lead-program story, but it advances the company into a demanding review-and-confirmation phase rather than resolving the approval debate.

What to watch next

U.S. confirmatory screening by year-end 2026

Original filing on SEC EDGAR

More uniQure N.V. news

uniQure FDA accepts Huntington’s BLA, but advisory panel looms | QURE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.